Potassium

Potassium

SCHEMBL6059809

Cc1noc(=O)[nH]1.[K]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22743968 0.72
SCHEMBL22681543 0.65
SCHEMBL22852477 0.65
SCHEMBL16921964 0.65
SCHEMBL22626700 0.65
SCHEMBL4896144 0.65
SCHEMBL2963261 0.63 ALDH1A1 (0.61)
SCHEMBL21649800 0.62
SCHEMBL21533466 0.62 CTH (0.39)
SCHEMBL22273330 0.62 CTH (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7012098-B2 Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers PHARMACIA CORPORATION (US) 2006-03-14 US disclosed
EP-1463495-A4 AGENTS AND METHODS FOR TREATMENT OF CANCER PHARMACIA CORP (US) 2005-11-16 EP disclosed
US-20050203082-A1 Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents PHARMACIA CORPORATION 2005-09-15 US disclosed
EP-1429777-A4 OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS PHARMACIA CORP (US) 2005-06-22 EP disclosed
EP-1534668-A1 CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID Pharmacia Corporation (US) 2005-06-01 EP disclosed
EP-1528921-A2 METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS Pharmacia Corporation (US) 2005-05-11 EP disclosed
WO-2005025620-A2 COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS PHARMACIA CORPORATION (US) 2005-03-24 WO disclosed
EP-1506040-A2 SELECTIVE INOS INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS Pharmacia Corporation (US) 2005-02-16 EP disclosed
EP-1505972-A2 A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES Pharmacia Corporation (US) 2005-02-16 EP disclosed
EP-1463495-A2 AGENTS AND METHODS FOR TREATMENT OF CANCER Pharmacia Corporation (US) 2004-10-06 EP disclosed
EP-1317421-A1 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS Pharmacia Corporation (US) 2003-06-11 EP disclosed
US-6545170-B2 For therapy of rheumatoid arthritis and in osteoarthritis, inflammatory bowel disease, cardivascular ischemia, diabetes, congestive heart failure, myocarditis, atherosclerosis, migraine, glaucoma, aortic aneurysm, reflux esophagitis PHARMACIA CORPORATION 2003-04-08 US disclosed
WO-2003026668-A1 OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS PHARMACIA CORPORATION (US) 2003-04-03 WO disclosed
WO-2003026638-A1 NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS PHARMACIA CORPORATION (US) 2003-04-03 WO disclosed
US-20030013702-A1 Agents and methods for treatment of cancer PHARMACIA CORPORATION 2003-01-16 US disclosed
WO-2002076395-A2 AGENTS AND METHODS FOR TREATMENT OF CANCER PHARMACIA CORPORATION (US) 2002-10-03 WO disclosed
US-20020143061-A1 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors PITZELE BARNETT S (US) 2002-10-03 US disclosed
US-20020103398-A1 2-Amino-2-alky-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors PHARMACIA CORPORATION 2002-08-01 US disclosed
WO-2002022562-A1 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS PHARMACIA CORPORATION (US) 2002-03-21 WO disclosed
WO-2002022557-A2 2-AMINO-2-ALKYL-4 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS PHARMACIA CORPORATION (US) 2002-03-21 WO disclosed